Examining the Progression: COVID-19 Vaccines and Myocarditis
A timeline of COVID-19 vaccines and myocarditis:
Sept. 22, 2020: The U.S. Centers for Disease Control and Prevention (CDC) identifies myocarditis as a potential side effect.
Oct. 30, 2020: The U.S. Food and Drug Administration (FDA) identifies myocarditis as a potential side effect.
December 2020: One case of pericarditis reported to the U.S. Vaccine Adverse Event Reporting System (VAERS) co-managed by the CDC and FDA.
Dec. 11, 2020: FDA authorizes the Pfizer-BioNTech vaccine for Americans 16 and older.
Dec. 13, 2020: CDC launches V-safe, a vaccine safety monitoring system, without including myocarditis as an adverse event.
Dec. 18, 2020: FDA authorizes the Moderna vaccine for Americans 18 and older.
2021:
Jan. 2021: Myocarditis cases spike in the U.S. military.
Jan. 2021: Cases of postvaccination myocarditis recorded in Israel.
Feb. 1, 2021: Israeli teenager hospitalized with myocarditis after Pfizer vaccination.
Feb. 18, 2021: Safety signal for myocarditis in VAERS triggered.
Feb. 19, 2021: Another safety signal for myocarditis triggered in VAERS.
Feb. 27, 2021: FDA authorizes Johnson & Johnson’s COVID-19 vaccine.
Feb. 28, 2021: Israeli officials privately alert CDC to reports of myocarditis following Pfizer vaccine.
March 2021: Reports of myocarditis continue to increase in VAERS.
March 2, 2021: CDC recommends Johnson & Johnson’s COVID-19 vaccine for adults.
March 3, 2021: Israeli authorities meet with hospital officials to discuss postvaccination heart problems.
March 4, 2021: Israeli officials confirm investigation into postvaccination pericarditis.
March 5, 2021: FDA holds meeting with advisors, but myocarditis not discussed.
March 6, 2021: Rutgers University mandates COVID-19 vaccination.
March 8, 2021: Australian health officials contact CDC about U.S. myocarditis cases.
March 9, 2021: U.S. internal memorandum acknowledges postvaccination myocarditis cases.
March 20, 2021: First postvaccination myocarditis case report published.
March 31, 2021: First death from postvaccination myocarditis reported in Israel.
April 2021: Reports of myocarditis cases continue to increase in VAERS.
April 13, 2021: CDC and FDA advise pause in administration of Johnson & Johnson’s vaccine due to blood clotting cases.
April 23, 2021: United States lifts recommended pause on Johnson & Johnson’s vaccine.
April 26, 2021: U.S. military officials track cases of myocarditis following mRNA vaccination.
May 2021: Reports of myocarditis cases continue to increase in VAERS.
May 10, 2021: FDA authorizes Pfizer’s COVID-19 vaccine for children aged 12 to 15.
May 12, 2021: Myocarditis is not discussed during meeting on Pfizer’s vaccine.
May 17, 2021: CDC workgroup states that myocarditis rates after vaccination are not higher than expected baseline rates.
May 18, 2021: States publicly report cases of myocarditis following COVID-19 vaccination.
May 18, 2021: First case report of an American with postvaccination myocarditis published.
May 19, 2021: CDC informs state officials of close monitoring of myocarditis cases after vaccination.
May 2021: CDC forms a team to review medical records for reported cases of postvaccination myocarditis.
These events outline the ongoing monitoring and investigation of myocarditis cases associated with COVID-19 vaccines.
Source link
